Geneos therapeutics secures $12 million in series a1 financing to advance personalized cancer immunotherapy programs

Plymouth meeting, pa., march 3, 2021 /prnewswire/ -- geneos therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its series a1 round, raising $12 million in financing. the...
INO Ratings Summary
INO Quant Ranking